Drug intelligence / Profile preview

ambroxol + guaifenesin + terbutaline

Development stage
Unknown
Lead developer
Med Manor Organics
Modality
Small Molecules
Administration
Oral
01

Overview

Kufril is a fixed-dose combination oral syrup manufactured by Med Manor Organics, primarily used to treat productive (wet) cough and chest congestion associated with respiratory conditions such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD). It contains three active ingredients: ambroxol, a mucolytic agent that thins and loosens thick mucus; guaifenesin, an expectorant that increases respiratory tract fluid to facilitate mucus clearance; and terbutaline, a beta-2 adrenergic receptor agonist (bronchodilator) that relaxes airway smooth muscles to improve airflow. Some formulations also include menthol for its cooling and soothing effects on the throat.

Brand names
KufrilKufril Syrup
Other names
ambroxol + guaifenesin + terbutalineambroxol/guaifenesin/terbutaline
02

Targets

GBA2 (Beta-glucosidase 2)SCN10A (Sodium channel protein type X alpha subunit)SCN9A (Sodium channel protein type 9 subunit alpha)ADRB2 (β2)GBA1 (Glucosylceramidase)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ambroxol + guaifenesin + terbutaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ambroxol + guaifenesin + terbutaline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call